|
|
|
|
|
CUSIP No. 29251M106
|
|
|
|
Page 3 of 4 Pages
|
Item 1.
|
Security and Issuer.
|
This Amendment No. 1 to the statement on Schedule 13D (this Statement) with respect to the shares of common stock, par value $0.01 per
share (the Shares), of Enanta Pharmaceuticals, Inc., a Delaware corporation (the Issuer), filed by Jay R. Luly, Ph.D. (Dr. Luly or the Reporting Person)
on January 18, 2019 (such statement, as amended herein, the Schedule 13D), amends the Schedule 13D as set forth below.
All
capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D. Except as specifically amended by this Amendment No. 1, items in the Schedule 13D are unchanged.
Item 3.
|
Source and Amount of Funds or Other Consideration.
|
Item 3 of the Schedule 13D is hereby amended and restated in full as follows:
Within the past sixty days, the Issuer issued 1,485 Shares to the Reporting Person pursuant to performance share units (PSUs) awarded on
March 1, 2018, which settled on February 12, 2020. The Issuer also issued 8,910 Shares to the Reporting Person pursuant to relative total stockholder return units (rTSRUs) awarded to the Reporting Person on March 1,
2018, which settled on February 12, 2020. Of those Shares, 3,122 were automatically forfeited by the Reporting Person on February 12, 2020 to cover withholding taxes due as a result of settlement of the PSUs and rTSRUs.
With respect to all other Shares beneficially owned by Dr. Luly, such Shares were awarded by the Issuer, as compensation for Dr. Lulys service
as the Chief Executive Officer and President of the Issuer, as performance awards, restricted stock units or stock options or were acquired by Dr. Luly through exercise of stock options using Dr. Lulys personal
funds. Dr. Lulys outstanding stock options are scheduled to continue to vest on a quarterly basis at an average rate of 24,875 Shares per quarter over the remainder of 2020.
Item 5.
|
Interest in Securities of the Issuer.
|
Item 5 of the Schedule 13D is hereby amended and restated in full as follows:
As of March 4, 2020, Dr. Luly beneficially owned 1,189,789 Shares, consisting of: (i) 649,689 Shares and (ii) 540,100 Shares issuable upon exercise
of outstanding options that are exercisable within the 60-day period following March 4, 2020. Dr. Luly has sole voting and dispositive power over all such shares. No person other than Dr. Luly
is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares beneficially owned by Dr. Luly.
The information set forth under Item 3 and the cover page of this Statement is incorporated herein by reference. Dr. Luly has not engaged in any
transactions with respect to the Shares during the 60 days before the date of this filing.
[signature page follows]